178 related articles for article (PubMed ID: 37060883)
1. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
4. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
Hacking S; Jin C; Komforti M; Liang S; Nasim M
Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.
Hongo T; Yamamoto H; Jiromaru R; Yasumatsu R; Kuga R; Nozaki Y; Hashimoto K; Matsuo M; Wakasaki T; Tamae A; Taguchi K; Toh S; Masuda M; Nakagawa T; Oda Y
Mod Pathol; 2021 Nov; 34(11):1966-1978. PubMed ID: 34218257
[TBL] [Abstract][Full Text] [Related]
6. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 Expression Can Affect Prognosis in Extramammary Paget's Disease.
Kawaguchi A; Akiba J; Kondo R; Sadashima E; Ogasawara S; Naito Y; Kusano H; Sanada S; Muto I; Nakama T; Yano H
Anticancer Res; 2021 Jan; 41(1):219-226. PubMed ID: 33419816
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
Kir G; Olgun ZC; Soylemez T; Aydin A; Demircan B; Kaya IA; McCluggage WG
Int J Gynecol Pathol; 2021 Nov; 40(6):575-586. PubMed ID: 33332859
[TBL] [Abstract][Full Text] [Related]
8. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
10. Programmed Death Ligand 1 (PD-L1) Expression and CD8 + Tumor-infiltrating Lymphocyte-based Tumor Immune Microenvironment Classification in Gynecologic Carcinosarcoma: Prognostic Impact and Implications for Therapy.
Ordner J; Gutierrez Amezcua JM; Marcus A; Shukla PS
Int J Gynecol Pathol; 2023 Jul; 42(4):364-375. PubMed ID: 35639400
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
12. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
Özcan D; Lade-Keller J; Tramm T
Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
[TBL] [Abstract][Full Text] [Related]
13. Programmed death ligand 1 (PD-L1) in colon cancer and its interaction with budding and tumor-infiltrating lymphocytes (TILs) as tumor-host antagonists.
Lang-Schwarz C; Melcher B; Hartmann A; Bertz S; Dregelies T; Lang-Schwarz K; Vieth M; Sterlacci W
Int J Colorectal Dis; 2021 Nov; 36(11):2497-2510. PubMed ID: 34170390
[TBL] [Abstract][Full Text] [Related]
14. Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?
Vagios S; Doulgeraki T; Giannikaki E; Kavoura E; Papadimitriou C; Gakiopoulou H; Pavlakis K
Anticancer Res; 2020 Mar; 40(3):1669-1676. PubMed ID: 32132073
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
Hu C; Tian S; Lin L; Zhang J; Ding H
Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
17. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
20. Classification of gallbladder cancer by assessment of CD8
Lin J; Long J; Wan X; Chen J; Bai Y; Wang A; Yang X; Wu Y; Robson SC; Sang X; Zhao H
BMC Cancer; 2018 Jul; 18(1):766. PubMed ID: 30055582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]